Gilead Sciences, Inc. (GILD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Gilead Sciences, Inc. (GILD) Healthcare & Pipeline Overview

Gilead Sciences, Inc. pioneers antiviral therapies, holding a dominant position in HIV/AIDS treatment and expanding into oncology and liver diseases. With a robust pipeline and strategic collaborations, Gilead addresses critical unmet medical needs globally, while facing patent expirations and competition from major pharmaceutical players.

What Is the Investment Thesis for GILD?

With a P/E ratio of 13.56 and a profit margin of 31.0%, Gilead demonstrates financial stability. Growth catalysts include pipeline advancements in oncology and continued revenue from HIV therapies. A dividend yield of 2.43% offers income potential. However, potential risks include patent expirations on key drugs and competition from other pharmaceutical companies. Investors should monitor the progress of Gilead's pipeline and its ability to maintain market share in key therapeutic areas.

Based on FMP financials and quantitative analysis

GILD Key Highlights

Market Cap of $186B reflects Gilead's significant presence in the biopharmaceutical industry.

• P/E Ratio of 13.56 indicates a potentially reasonable valuation compared to earnings.
• Profit Margin of 31.0% highlights Gilead's efficiency in converting revenue into profit.
• Gross Margin of 79.4% demonstrates strong pricing power and cost management in its product portfolio.
• Dividend Yield of 2.43% provides an income stream for investors, supported by Gilead's cash flow.

Who Are GILD's Competitors?

GILD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GILD's Key Strengths?

Strong portfolio of HIV/AIDS therapies.

• Established presence in liver disease treatment.
• Expanding oncology business through Kite Pharma acquisition.
• Robust pipeline of new drug candidates.

What Are GILD's Weaknesses?

Reliance on a few key products for revenue.

• Patent expirations on key drugs.
• Exposure to biosimilar competition.
• Dependence on collaborations for pipeline expansion.

What Could Drive GILD Stock Higher?

Clinical trial results for new oncology drug candidates.

• Continued revenue growth from Biktarvy in HIV treatment.
• Expansion of cell therapy business through new indications for Yescarta and Tecartus.
• Regulatory approvals for new therapies in development.
• Strategic collaborations to expand pipeline and access new technologies.

What Are the Key Risks for GILD?

Insider selling — insiders were net sellers of roughly $8.1M recently.

• Patent expirations on key drugs, leading to generic competition.
• Competition from other pharmaceutical companies in key therapeutic areas.
• Pricing pressures from government and payers.
• Clinical trial failures.
• Regulatory challenges.

What Are the Growth Opportunities for GILD?

• Growth opportunity 1: Expansion in Oncology: Gilead's acquisition of Kite Pharma provides a platform for growth in cell therapy. The market for cell therapies is projected to reach $51.2 billion by 2030, driven by advancements in personalized medicine and increasing prevalence of cancer. Gilead's Yescarta and Tecartus offer significant potential, with ongoing research exploring new indications and combinations. Success in oncology will diversify Gilead's revenue streams and reduce reliance on HIV therapies.
• Growth opportunity 2: Advancements in HIV Treatment: Gilead continues to innovate in HIV treatment, developing long-acting therapies and potential cures. The global HIV treatment market is expected to grow, driven by increasing access to treatment and prevention efforts. Gilead's Biktarvy remains a leading therapy, and the company is exploring new approaches, such as broadly neutralizing antibodies, to achieve long-term remission. These advancements could solidify Gilead's dominance in HIV care.
• Growth opportunity 3: Strategic Collaborations: Gilead's collaborations with companies like Arcus Biosciences and Merck & Co. provide access to novel technologies and drug candidates. These partnerships expand Gilead's pipeline and diversify its research efforts. By collaborating with innovative companies, Gilead can accelerate the development of new therapies and address unmet medical needs in various therapeutic areas. Successful collaborations can lead to significant revenue opportunities and strengthen Gilead's competitive position.
• Growth opportunity 4: Geographic Expansion: Gilead has the opportunity to expand its presence in emerging markets, where access to healthcare is increasing. These markets offer significant growth potential for Gilead's existing products and pipeline candidates. By establishing partnerships and distribution networks in these regions, Gilead can reach new patient populations and drive revenue growth. Successful geographic expansion requires navigating regulatory hurdles and adapting to local market conditions.
• Growth opportunity 5: Liver Disease Therapies: Gilead has a strong portfolio of therapies for liver diseases, including hepatitis B and hepatitis C. The market for liver disease treatments is expected to grow, driven by increasing prevalence of these conditions and advancements in diagnostic technologies. Gilead's Vemlidy and Epclusa offer effective treatment options, and the company is exploring new approaches to address unmet needs in liver disease management. Continued innovation in this area can drive revenue growth and solidify Gilead's position as a leader in liver disease therapies.

What Are GILD's Competitive Advantages?

• Patent protection on key drugs provides exclusivity and pricing power.
• Strong brand recognition and reputation in HIV/AIDS treatment.
• Extensive distribution network and established relationships with healthcare providers.
• Expertise in drug development and regulatory affairs.
• Strategic collaborations that provide access to novel technologies.

What Does GILD Do?

Gilead Sciences, Inc. was founded in 1987 with a vision to advance the care of patients suffering from life-threatening diseases. Initially focused on antiviral medicines, Gilead achieved a breakthrough with Tamiflu, an influenza treatment. The company solidified its position in HIV/AIDS treatment with a series of innovative drugs, including Truvada, Atripla, and Biktarvy, transforming the landscape of HIV care. Gilead's portfolio extends to liver diseases, with treatments like Harvoni and Epclusa for hepatitis C, achieving high cure rates. Expanding into oncology, Gilead acquired Kite Pharma, adding cell therapies like Yescarta and Tecartus to its offerings. The company's global reach spans the United States, Europe, and other international markets. Gilead collaborates with various companies, including Arcus Biosciences and Merck & Co., to develop new therapies and expand its pipeline. Headquartered in Foster City, California, Gilead continues to focus on addressing unmet medical needs through scientific innovation and strategic partnerships.

What Products and Services Does GILD Offer?

• Develops and commercializes antiviral drugs for HIV/AIDS.
• Offers treatments for liver diseases, including hepatitis B and C.
• Provides cell therapies for certain types of cancer.
• Researches and develops new therapies for life-threatening diseases.
• Collaborates with other companies to expand its pipeline.
• Markets its products globally, including in the United States and Europe.
• Focuses on areas of unmet medical need.

How Does GILD Make Money?

• Develops and patents pharmaceutical products.
• Conducts clinical trials to demonstrate safety and efficacy.
• Obtains regulatory approvals from agencies like the FDA.
• Manufactures and distributes its products globally.
• Generates revenue through sales of its patented drugs.

What Industry Does GILD Operate In?

Gilead Sciences operates in the highly competitive drug manufacturing industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The industry is driven by innovation, with companies constantly seeking to develop new therapies for unmet medical needs. Gilead competes with major pharmaceutical companies like MRK: Merck & Co., Inc. and PFE: Pfizer Inc. The market is influenced by factors such as aging populations, increasing healthcare spending, and advancements in biotechnology. Gilead's focus on antiviral therapies and oncology positions it to capitalize on these trends.

Who Are GILD's Key Customers?

• Patients with HIV/AIDS.
• Patients with liver diseases, such as hepatitis B and C.
• Patients with certain types of cancer.
• Hospitals and clinics that administer Gilead's therapies.
• Government healthcare programs that reimburse for Gilead's products.

Company Profile

Gilead Sciences, Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Foster City, US. The company is led by CEO Daniel O'Day. GILD has traded publicly since 1992.

Gilead Sciences, Inc. Financial Trajectory

Gilead Sciences, Inc. (GILD) reported $7.80B in revenue for Q2 FY2026, reflecting 12.1% growth compared to the prior quarter. The company recorded a net loss of $10.50B, with diluted EPS of $-8.45. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, GILD averaged $-0.67 in diluted EPS.

How Gilead Sciences, Inc. Is Valued

Gilead Sciences, Inc. carries a market capitalization of $186B, placing it in the large-cap category. Analyst price targets span from $123.00 to $180.00, with a consensus of $151.25. At the current price of $149.92, that implies approximately 1% upside potential. Relative to its peer group, GILD's quantitative score of 64/100 is below the peer average of 76/100.

Return on equity for Gilead Sciences, Inc. stands at 43.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 13.3%, showing how much profit it generates from its asset base. GILD trades at a trailing price-to-earnings ratio of 13.56, below the Healthcare sector average of ~21.60x. A current ratio of 1.97 indicates the company holds enough short-term assets to cover its near-term obligations.

Gilead Sciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.55 places it in the safe zone, indicating low near-term bankruptcy risk.

Gilead Sciences, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 9.7% above estimates on average.

Over the past six months, Gilead Sciences, Inc. insiders filed 30 SEC Form 4 transactions — 20 sales and 10 purchases. On net that is roughly 57K shares disposed (about $8.1M), a signal worth weighing alongside the fundamentals.

GILD Financials

GILD Latest News

GILD Analyst Consensus

GILD MoonshotScore

Latest Gilead Sciences, Inc. Analysis

Common Questions About GILD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources